Personalized antibiotic dosing could save ICU pneumonia patients
NCT ID NCT04986254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 179 ICU patients with pneumonia to figure out the best doses of common antibiotics. Researchers took blood and lung fluid samples to measure how the drugs move through the body. The goal was to create personalized dosing plans that ensure enough antibiotic reaches the infection site, which could improve treatment and fight drug resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antibiotics (benzylpenicillin, ceftriaxone, meropenem, piperacillin/tazobactam)
What this could lead to
If successful, this could lead to personalized antibiotic dosing for ICU pneumonia patients, potentially improving cure rates and reducing antibiotic resistance.
What could go wrong
This was a small, early-stage study (179 participants) focused on measuring drug levels, not on patient outcomes. The proposed dosing regimens still need to be tested in larger trials to see if they actually improve survival or recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire de Nimes
Nîmes, France
-
Chinese University of Hong Kong
Hong Kong, Hong Kong
-
Royal Brisbane and Women's Hospital
Brisbane, Australia
-
The Alfred
Melbourne, Australia
-
University Hospital, Ghent
Ghent, Belgium
-
University of Malaya
Kuala Lumpur, Malaysia